Cardiovascular and metabolic risks in patients with obesity and non-alcoholic fatty liver disease

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Article contains the discussion about the role of non-alcoholic fatty liver disease (NAFLD) in patients with obesity and other metabolic disorders in the risk of type 2 diabetes mellitus (DM2) and cardiovascular disease development. Modern data on the prevalence of NAFLD in Russia and other countries are presented. Particular attention is paid to the assessment of the etiological factors leading to the development of NAFLD and its progression from fatty hepatosis and non-alcoholic steatohepatitis to fibrosis and cirrhosis of liver. The results of clinical studies from last years, indicating a high risk of DM2 developing and cardiovascular morbidity and mortality in the presence of the metabolic syndrome in combination with NAFLD are analyzed. Approaches to the diagnosis and treatment of NAFLD patients are presented in accordance with current advisory and consensus documents. The possibilities of using ursodeoxycholic acid in the complex therapy of patients with metabolic syndrome, dyslipidemia, and NAFLD are discussed.

Full Text

Restricted Access

About the authors

Oksana A. Kislyak

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Author for correspondence.
Email: kisliakoa@mail.ru
ORCID iD: 0000-0002-2028-8748

MD, Professor, Head of the Department of Faculty Therapy of the Faculty of General Medicine

Russian Federation, Moscow

Anzhela A. Mikaelyan

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: poppysinclair8@gmail.com
ORCID iD: 0000-0002-5527-5752

Postgraduate Student of the Department of Faculty Therapy of the Faculty of General Medicine

Russian Federation, Moscow

Antonina V. Starodubova

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia; Federal Research Center for Nutrition, Biotechnology and Food Safety of the Ministry of Healthcare of Russia

Email: avs.ion@yandex.ru
ORCID iD: 0000-0001-9262-9233

MD, Associate Professor, Deputy Director for Scientific and Medical Work, Head of the Department of Cardiovascular Pathology and Diet Therapy of Federal Research Center for Nutrition, Biotechnology and Food Safety of the Ministry of Healthcare of Russia, Professor of the Department of Faculty Therapy of The Faculty of General Medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Russian Federation, Moscow; Moscow

Svetlana D. Kosyura

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: kosyurasd@yandex.ru
ORCID iD: 0000-0003-2634-8067

PhD in Medical Sciences, Associate Professor of the Department of Faculty Therapy of the Faculty of General MedicineСердечно-сосудистые и метаболические риски у пациентов с ожирением и неалкогольной жировой болезнью печени

Russian Federation, Moscow

References

  1. Centers for Diseases Control and Prevention (CDC). Adult obesity facts. CDC Published 2020. URL: https://www.cdc.gov/obesity/data/adult.html (date of access – 01.04.2023).
  2. Flegal K.M., Kit B.K., Orpana H., Graubard B.I. Association of all-cause mortality with overweight and obesity using standard body mass index categories: A systematic review and meta-analysis. JAMA. 2013; 309(01): 71–82. https://dx.doi.org/10.1001/jama.2012.113905.
  3. Kyle T.K., Dhurandhar E.J., Allison D.B. Regarding obesity as a disease: Evolving policies and their implications. Endocrinol Metab Clin North Am. 2016; 45(03): 511–20. https://dx.doi.org/10.1016/j.ecl.2016.04.004.
  4. Клинические рекомендации. Рекомендации по ведению больных с метаболическим синдромом. Минздрав России, Российское медицинское общество по артериальной гипертонии. 2013. Доступ: https://mzdrav.rk.gov.ru/file/mzdrav_18042014_Klinicheskie_rekomendacii_Metabolicheskij_sindrom.pdf (дата обращения – 01.04.2023). [Clinical guidelines. Recommendations for the management of patients with metabolic syndrome. Ministry of Healthcare of Russia, Russian Medical Society for Arterial Hypertension. 2013. URL: https://mzdrav.rk.gov.ru/file/mzdrav_18042014_Klinicheskie_rekomendacii_Metabolicheskij_sindrom.pdf (date of access – 01.04.2023) (In Russ.)].
  5. Kanwal F., Kramer J.R., Duan Z. et al. Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans. Clin Gastroenterol Hepatol. 2016; 14(02): 301–8.e1–2. https://dx.doi.org/10.1016/j.cgh.2015.08.010.
  6. Li Z., Xue J., Chen P. et al. Prevalence of nonalcoholic fatty liver disease in mainland of China: A meta-analysis of published studies. J Gastroenterol Hepatol. 2014; 29(1): 42–51. https://dx.doi.org/10.1111/jgh.12428.
  7. Лазебник Л.Б., Голованова Е.В., Туркина С.В. с соавт. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021; 185(1): 4–52. [Lazebnik L.B., Golovanova E.V., Turkina S.V. et al. Non-alcoholic fatty liver disease in adults: Clinic, diagnostics, treatment. Guidelines for therapists, third version. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2021; 185(1): 4–52 (In Russ.)]. https://dx.doi.org/10.31146/1682-8658-ecg-185-1-4-52. EDN: KJLOJV.
  8. Eslam M., Sanyal A.J., George J. et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020; 158(7): 1999–2014.e1. https://dx.doi.org/10.1053/j.gastro.2019.11.312.
  9. Eslam M., Newsome P.N., Sarin S.K. et al. A new defnition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73(1): 202–9. https://dx.doi.org/10.1016/j.jhep.2020.03.039.
  10. Grundy S.M., Cleeman J.I., Daniels S.R. et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung and Blood Institute scientific statement. Circulation. 2005;1 12(17): 2735–52. https://dx.doi.org/10.1161/CIRCULATIONAHA.105.169404.
  11. Ye Q., Zou B., Yeo Y.H. et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5(8): 739–52. https://dx.doi.org/10.1016/S2468-1253(20)30077-7.
  12. Sheka A.C., Adeyi O., Thompson J. et al. Nonalcoholic steatohepatitis: A review. JAMA. 2020; 323(12): 1175–83. https://dx.doi.org/10.1001/jama.2020.2298.
  13. Maurice J., Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond). 2018; 18(3): 245–50. https://dx.doi.org/10.7861/clinmedicine.18-3-245.
  14. Маевская М.В., Котовская Ю.В., Ивашкин В.Т. с соавт. Национальный консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями. Терапевтический архив. 2022; 94(2): 216–253. [Maevskaya M.V., Kotovskaya Yu.V., Ivashkin V.T. et al. The national consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskiy arkhiv = Therapeutic Archive. 2022; 94(2): 216–253 (In Russ.)]. https://dx.doi.org/10.26442/00403660.2022.02.201363. EDN: CODINB.
  15. Ballestri S., Zona S., Targher G. et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016; 31(5): 936–44. https://dx.doi.org/10.1111/jgh.13264.
  16. Wagner R., Heni M., Tabak A.G. et al. Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med. 2021; 27(1): 49–57. https://dx.doi.org/10.1038/s41591-020-1116-9.
  17. Ekstedt M., Hagstrom H., Nasr P. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015; 61(5): 1547–54. https://dx.doi.org/10.1002/hep.27368.
  18. Quek J., Ng C.H., Tang A.S. et al. Metabolic associated fatty liver disease increases the risk of systemic complications and mortality. A meta-analysis and systematic review of 12620736 individuals. Endocr Pract. 2022; 28(7): 667–72. https://dx.doi.org/10.1016/j.eprac.2022.03.016.
  19. Sinn D.H., Kang D., Chang Y. et al. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: A retrospective cohort study. Gut. 2017; 66(2): 323–29. https://dx.doi.org/10.1136/gutjnl-2016-311854.
  20. Mach F., Baigent C., Catapano A.L. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111–88. https://dx.doi.org/10.1093/eurheartj/ehz455.
  21. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российское кардиологическое общество, Национальное общество профилактической кардиологии. Доступ: https://scardio.ru/content/Guidelines/Kardiovascular_profilaktika_2022.pdf (дата обращения – 01.04.2023). [Cardiovascular prevention 2022. Russian national guidelines. Russian Society of Cardiology, National Society of Preventive Cardiology. URL: https://scardio.ru/content/Guidelines/Kardiovascular_profilaktika_2022.pdf (date of access – 01.04.2023) (In Russ.)].
  22. Gorczyca-Glowacka I., Wełnicki M., Mamcarz A. et al. Metabolic associated fatty liver disease and cardiovascular risk: The expert opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society. Kardiol Pol. 2023; 81(2): 207–14. https://dx.doi.org/10.33963/KP.a2023.0022.
  23. Hashem A., Khalouf A., Acosta A. Management of obesity and nonalcoholic fatty liver disease: A literature review. Semin Liver Dis 2021; 41(4): 435–47. https://dx.doi.org/10.1055/s-0041-1731704.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies